EUTHYROX (levothyroxine sodium) by Pfizer is synthesis. First approved in 2002.
Drug data last refreshed 8h ago
EUTHYROX (levothyroxine sodium) is an oral tablet containing synthetic thyroid hormone used to treat hypothyroidism and congenital hypothyroidism. It works by diffusing into cell nuclei and binding to thyroid receptors on DNA, activating gene transcription and protein synthesis to restore normal metabolic function. Approximately 80% of T3 production derives from peripheral T4 deiodination.
EUTHYROX faces significant competitive pressure in a crowded levothyroxine market with LOE approaching, suggesting smaller team and focus on defensive positioning rather than growth initiatives.
synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
BE of Euthyrox® Tablets (Merck Nantong Versus Merck Darmstadt Sites)
Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form
Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors
Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation
Worked on EUTHYROX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
EUTHYROX represents a mature, commodity-like product in a highly competitive market with zero identified linked job openings, suggesting limited active hiring or team expansion. Career opportunities are typically confined to cost-management, access, and patient support roles rather than growth-oriented positions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo